ClinicalTrials.gg
CompletedNCT03149848Updated Sep 17, 2020Results posted

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

A Phase 1 interventional study of Cabotegravir and Rifabutin in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-17.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
33rd of 36
15 · median 200
Started
2017
with 3 others
Phase 1
10 of 36
none open now
Registered
13th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 33rd largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 13th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This is a Phase I, single-center, open-label, fixed-sequence, 2-period crossover study in healthy adults to evaluate the effect of oral rifabutin (RBT) 300 milligram (mg) on the pharmacokinetics of oral cabotegravir (CAB) 30 milligram ( mg). This study will evaluate the drug-drug interaction (DDI) potential between CAB and RBT to inform dosing strategies for tuberculosis in subjects receiving CAB for human immunodeficiency virus (HIV) treatment or prevention. In Treatment Period 1 (Treatment A) participants will receive CAB 30 mg once daily for 14 days, followed by Treatment Period 2 (Treatment B) where participants will receive RBT 300 mg once daily with CAB 30 mg once daily for 14 days. The total study duration will be approximately for 10 weeks. Approximately 15 healthy subjects will be enrolled to ensure that 12 subjects complete dosing and critical assessments.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Keywords

  • Tuberculosis
  • Human Immunodeficiency Virus
  • Rifabutin
  • Drug-drug interaction
  • Cabotegravir
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 15 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 65 years of age inclusive, at the time of signing the .
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Additionally, laboratory assessments that are specifically listed in the inclusion or exclusion criteria and are outside of the reference range can be repeated once during the screening period.
  • Body weight >=50 kilogram (kg) and (BMI) within the range 18.5 - 31.0 kg/ meter square (kg/m\^2) (inclusive).
  • A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test), not lactating, and if she is of:

    • Non- defined as pre-menopausal with documented tubal ligation, hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Bilateral Oophorectomy, defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause FSH: >40 milli international unit/mililiter (MIU/mL) and estradiol \<40 picogram (pg)/mL (\<147 picomoles/L) is confirmatory];
    • Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication until the completion of the follow-up visit.

The investigator is responsible for ensuring that subjects understand how to properly use these methods of .

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
  • , alkaline phosphatase and \<=1x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • White blood cell count and in the normal range.

Exclusion criteria

Exclusion Criteria

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of cardiovascular disease including

    • Exclusion criteria for screening (a single repeat is allowed for eligibility determination): male subjects with heart rate \<45 and >100 beats per minute (bpm) and female subjects with heart rate \<50 and >100 bpm, QRS duration (males and females) >120 millisecond (msec), corrected by Fridericia's formula (QTcF) >450 msec for males and females.
    • Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization).
    • History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease.
    • Conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree (type II) or higher], Wolf Parkinson White [WPW] syndrome) which in the opinion of the principal Investigator and Viiv Medical Monitor, will interfere with the safety for the individual subject.
    • Sinus pauses >3 seconds.
    • Any significant arrhythmia which, in the opinion of the principal Investigator and ViiV Medical Monitor, will interfere with the safety for the individual subject.
    • Non-sustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia.
  • History of inflammatory bowel disease.
  • History of cholecystectomy or other gastrointestinal surgery (except appendectomy more than three months prior to study).
  • History of peptic ulceration or pancreatitis within the preceding 6 months of screening.
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
  • Current or past history of uveitis.
  • Any other medical condition which, in the judgment of the investigator and medical monitor, could jeopardize the safety of the subject or the integrity of the data derived from that subject. This includes but is not limited to any pre-existing condition that interferes with normal gastrointestinal anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of the study drug.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and ViiV Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks. One drink is equivalent to 12 gram of alcohol, 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • A history of regular use of tobacco, or nicotine-containing products within 30 days prior to screening.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • Presence of surface antigen (HBsAg) positivity at screening or within 3 months prior to first dose of study treatment. Positive Hepatitis B core antibody (HBcAb) with negative hepatitis B surface antibody should also be excluded.
  • Positive antibody test.
  • A positive pre-study drug/alcohol screen.
  • A positive test for antibody.
  • A positive QuantiFERON Gold test or clinical evidence of tuberculosis (TB) infection.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.

    Drug: Cabotegravir

  • Experimental
    Treatment B

    Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.

    Drug: Cabotegravir · Drug: Rifabutin

Interventions

  • It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate

  • It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel

07

What researchers measure

Primary outcomes

  1. Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. AUC (0 to tau) was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. PK Summary Population included participants who had CAB PK parameter estimates from both serial PK sampling time periods 1 and 2. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

  2. Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Cmax was determined directly from the concentration-time data. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

Secondary outcomes

  1. Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

  2. Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Tmax was determined directly from the concentration-time data.

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

  3. Assessment of Plasma CAB PK Parameter: Terminal Phase Half-life (t1/2)

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Apparent terminal half-life was calculated as: t1/2 = ln2 / Lambda_z, where Lambda_z is the terminal phase rate constant. Plasma t1/2 was not estimated for either period due to limited PK sampling in the terminal phase.

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

  4. Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)

    Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. CL/F was calculated as CL/F =Dose/AUC(0 to tau).

    Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

  5. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. Safety Population comprised of all participants who enrolled in the study and received at least one dose of study drug.

    Time frame: Up to 10 weeks

  6. Concurrent Medication Assessment in Treatment Period 1 and 2

    Concurrent medications included paracetamol and ibuprofen. Number of participants who took concurrent medications during the study are presented.

    Time frame: Up to 10 weeks

  7. Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

    Blood samples for hematology assessment were collected for basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  8. Assessment of Hematology Parameters: Hematocrit and Reticulocytes/Erythrocytes (R/E)

    Blood samples for hematology assessment were collected for Hematocrit and R/E. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  9. Assessment of Hematology Parameter: Hemoglobin

    Blood samples for hematology assessment was collected for Hemoglobin. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  10. Assessment of Hematology Parameter: Eryrocyte Mean Corpuscular Hemoglobin

    Blood samples for hematology assessment was collected for Eryrocyte Mean Corpuscular Hemoglobin. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  11. Assessment of Hematology Parameter: Erythrocye Mean Corpuscular Volume

    Blood samples for hematology assessment was collected for Erythrocyte Mean Corpuscular Volume. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  12. Assessment of Hematology Parameters: Erythrocytes and Reticulocytes

    Blood samples for hematology assessment were collected for Erythrocytes and reticulocytes. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  13. Assessment of Hematology Parameters: Erythrocytes Distribution Width (EDW)

    Blood samples for hematology assessment was collected for EDW. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  14. Assessment of Clinical Chemistry Parameters: Albumin and Protein

    Samples for clinical chemistry assessment were collected for Albumin and Protein. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  15. Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT)

    Samples for clinical chemistry assessment were collected for ALP, AST, ALT, CK and GGT. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  16. Assessment of Clinical Chemistry Parameters: Direct Bilirubin (DB), Bilirubin and Creatinine

    Samples for clinical chemistry assessment were collected for DB, bilirubin and creatinine. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  17. Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea

    Samples for clinical chemistry assessment were collected for Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  18. Number of Participants With Abnormal Urinalysis Result

    Samples for urinalysis assessment was collected at Day -1, Day 13, Day 21, Day 27 and during follow-up period (10 to 14 daya after last dose). Data for participants with abnormal urinalysis results has been presented.

    Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)

  19. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    ECG measurements was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Data has been presented for Period 1, Day 14 pre-dose which showed abnormal- not clinically significant ECG finding. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day 1, 14, 21, 28 and follow-up (10 to 14 days after last dose)

  20. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs measurement was done in semi-supine position after 10 minutes rest and included SBP and DBP. Two blood pressure measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single blood pressure was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline to follow-up (10 to 14 days after last dose)

  21. Change From Baseline in Pulse Rate

    Vital signs measurement was done in semi-supine position after 10 minutes rest and included pulse rate. Two pulse rate measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single pulse rate was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline to follow-up (10 to 14 days after last dose)

08

Results

Posted Feb 4, 2019

Participant flow

A total of 15 participants were enrolled from one center in the United Kingdom. The study was conducted from 06 June 2017 to 07 September 2017.

Period 1 (Day 1 to Day 14)
Participant flow — Period 1 (Day 1 to Day 14)
MilestoneCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Started15
Completed14
Not completed1
Withdrew: Protocol-defined stopping criteria1
Period 2 (Day 15 to Day 28)
Participant flow — Period 2 (Day 15 to Day 28)
MilestoneCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Started14
Completed12
Not completed2
Withdrew: Adverse event2

Outcome measures

PrimaryAssessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. AUC (0 to tau) was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. PK Summary Population included participants who had CAB PK parameter estimates from both serial PK sampling time periods 1 and 2. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Reported as:
Geometric mean · Microgram * hour per milliliter
Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])
Microgram * hour per milliliterCAB 30 mgRBT 300 mg + CAB 30 mg
Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])103.978 ± 28.381.715 ± 29.9
Statistical analysis
  • CAB 30 mg vs RBT 300 mg + CAB 30 mg · Ratio: 0.786 · 90% CI 0.743 to 0.831
PrimaryAssessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Cmax was determined directly from the concentration-time data. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Reported as:
Geometric mean · Micrograms per milliliter
Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)
Micrograms per milliliterCAB 30 mgRBT 300 mg + CAB 30 mg
Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)6.356 ± 24.75.246 ± 24.3
Statistical analysis
  • CAB 30 mg vs RBT 300 mg + CAB 30 mg · Ratio: 0.825 · 90% CI 0.761 to 0.895
SecondaryAssessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Reported as:
Geometric mean · Micrograms per milliliter
Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)
Micrograms per milliliterCAB 30 mgRBT 300 mg + CAB 30 mg
Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)3.359 ± 34.32.479 ± 36.3
Statistical analysis
  • CAB 30 mg vs RBT 300 mg + CAB 30 mg · Ratio: 0.738 · 90% CI 0.702 to 0.776
SecondaryAssessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Tmax was determined directly from the concentration-time data.

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Reported as:
Median · Hours
Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)
HoursCAB 30 mgRBT 300 mg + CAB 30 mg
Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)3.000 (1.00 to 4.00)2.500 (1.00 to 4.00)
SecondaryAssessment of Plasma CAB PK Parameter: Terminal Phase Half-life (t1/2)

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Apparent terminal half-life was calculated as: t1/2 = ln2 / Lambda_z, where Lambda_z is the terminal phase rate constant. Plasma t1/2 was not estimated for either period due to limited PK sampling in the terminal phase.

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28

No measurements were reported for this outcome.

SecondaryAssessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)

Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. CL/F was calculated as CL/F =Dose/AUC(0 to tau).

Time frame:
Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Reported as:
Geometric mean · Liters per hour
Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)
Liters per hourCAB 30 mgRBT 300 mg + CAB 30 mg
Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)0.289 ± 28.30.367 ± 29.9
Statistical analysis
  • CAB 30 mg vs RBT 300 mg + CAB 30 mg · Ratio: 1.272 · 90% CI 1.204 to 1.345
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. Safety Population comprised of all participants who enrolled in the study and received at least one dose of study drug.

Time frame:
Up to 10 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCAB 30 mgRBT 300 mg + CAB 30 mg
Any AEs17
Any SAEs01
SecondaryConcurrent Medication Assessment in Treatment Period 1 and 2

Concurrent medications included paracetamol and ibuprofen. Number of participants who took concurrent medications during the study are presented.

Time frame:
Up to 10 weeks
Reported as:
Count of participants · Participants
Concurrent Medication Assessment in Treatment Period 1 and 2
ParticipantsCAB 30 mgRBT 300 mg + CAB 30 mg
Paracetamol03
Ibuprofen01
SecondaryAssessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Blood samples for hematology assessment were collected for basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · 10^9 cells/Liter
Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
10^9 cells/LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Basophils, Day -1, n=150.025 ± 0.0119
Basophils, On-treatment, Period 1 Day 13, n=140.031 ± 0.0141
Basophils, On-treatment, Period 2 Day 21, n=130.028 ± 0.0124
Basophils, On-treatment, Period 2 Day 27, n=120.018 ± 0.0106
Basophils, Follow-up, Period 1 Day 13, n=10.030 ± NA
Basophils, Follow-up, Period 2 Day 21, n=10.010 ± NA
Basophils, Follow-up, Period 2 Day 27, n=10.010 ± NA
Basophils, Follow-up, n=150.023 ± 0.0098
Eosinophils, On-treatment, Day -1, n=150.259 ± 0.2001
Eosinophils, On-treatment, Period 1 Day 13, n=140.285 ± 0.2264
Eosinophils, On-treatment, Period 2 Day 21, n=130.315 ± 0.2306
Eosinophils, On-treatment, Period 2 Day 27, n=120.219 ± 0.2815
Eosinophils, Follow-up, Period 1 Day 13, n=10.370 ± NA
Eosinophils, Follow-up, Period 2 Day 21, n=10.010 ± NA
Eosinophils, Follow-up, Period 2 Day 27, n=10.120 ± NA
Eosinophils, Follow-up, n=150.273 ± 0.2621
Lymphocytes, Day -1, n=152.509 ± 0.7383
Lymphocytes, On-treatment, Period 1 Day 13, n=142.224 ± 0.6596
Lymphocytes, On-treatment, Period 2 Day 21, n=132.071 ± 0.8625
Lymphocytes, On-treatment, Period 2 Day 27, n=121.551 ± 0.6554
Lymphocytes, Follow-up, Period 1 Day 13, n=11.200 ± NA
Lymphocytes, Follow-up, Period 2 Day 21, n=10.310 ± NA
Lymphocytes, Follow-up, Period 2 Day 27, n=10.480 ± NA
Lymphocytes, Follow-up, n=152.140 ± 0.7373
Monocytes, Day -1, n=150.561 ± 0.1570
Monocytes, On-treatment, Period 1 Day 13, n=140.548 ± 0.1397
Monocytes, On-treatment, Period 2 Day 21, n=130.628 ± 0.1579
Monocytes, On-treatment, Period 2 Day 27, n=120.488 ± 0.1442
Monocytes, Follow-up, Period 1 Day 13, n=10.360 ± NA
Monocytes, Follow-up, Period 2 Day 21, n=10.480 ± NA
Monocytes, Follow-up, Period 2 Day 27, n=10.790 ± NA
Monocytes, Follow-up, n=150.545 ± 0.1503
Neutrophils, Day -1, n=154.279 ± 1.2269
Neutrophils, On-treatment, Period 1 Day 13, n=143.306 ± 0.9964
Neutrophils, On-treatment, Period 2 Day 21, n=132.818 ± 1.0823
Neutrophils, On-treatment, Period 2 Day 21, n=121.979 ± 0.6006
Neutrophils, Follow-up, Period 1 Day 13, n=12.340 ± NA
Neutrophils, Follow-up, Period 2 Day 21, n=13.830 ± NA
Neutrophils, Follow-up, Period 2 Day 27, n=13.970 ± NA
Neutrophils, Follow-up, n=152.840 ± 0.8665
Platelets, Day -1, n=15234.7 ± 34.58
Platelets, On-treatment, Period 1 Day 13, n=14210.7 ± 31.46
Platelets, On-treatment, Period 2 Day 21, n=13214.5 ± 31.04
Platelets, On-treatment, Period 2 Day 27, n=12193.9 ± 34.47
Platelets, Follow-up, Period 1 Day 13, n=1206.0 ± NA
Platelets, Follow-up, Period 2 Day 21, n=1206.0 ± NA
Platelets, Follow-up, Period 2 Day 27, n=1169.0 ± NA
Platelets, Follow-up, n=15229.8 ± 45.57
Leukocytes, Day -1, n=157.633 ± 1.6572
Leukocytes, On-treatment, Period 1 Day 13, n=146.394 ± 1.5268
Leukocytes, On-treatment, Period 2 Day 21, n=135.859 ± 1.5835
Leukocytes, On-treatment, Period 2 Day 27, n=124.256 ± 1.3035
Leukocytes, Follow-up, Period 1 Day 13, n=14.300 ± NA
Leukocytes, Follow-up, Period 2 Day 21, n=14.640 ± NA
Leukocytes, Follow-up, Period 2 Day 27, n=15.370 ± NA
Leukocytes, Follow-up, n=155.822 ± 1.3583
SecondaryAssessment of Hematology Parameters: Hematocrit and Reticulocytes/Erythrocytes (R/E)

Blood samples for hematology assessment were collected for Hematocrit and R/E. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Proportion of red blood cells in blood
Assessment of Hematology Parameters: Hematocrit and Reticulocytes/Erythrocytes (R/E)
Proportion of red blood cells in bloodCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Hematocrit, Day -1, n=150.411 ± 0.02107
Hematocrit, On-treatment, Period 1 Day 13, n=140.427 ± 0.02432
Hematocrit, On-treatment, Period 2 Day 21, n=130.415 ± 0.02277
Hematocrit, On-treatment, Period 2 Day 27, n=120.425 ± 0.02139
Hematocrit, Follow-up, Period 1 Day 13, n=10.413 ± NA
Hematocrit, Follow-up, Period 2 Day 21, n=10.419 ± NA
Hematocrit, Follow-up, Period 2 Day 27, n=10.412 ± NA
Hematocrit, Follow-up, n=150.411 ± 0.01766
R/E, Day -1, n=150.008 ± 0.00228
R/E, On-treatment, Period 1 Day 13, n=140.008 ± 0.00248
R/E, On-treatment, Period 2 Day 21, n=130.008 ± 0.00209
R/E, On-treatment, Period 2 Day 27, n=120.006 ± 0.00219
R/E, Follow-up, Period 1 Day 13, n=10.013 ± NA
R/E, Follow-up, Period 2 Day 21, n=10.009 ± NA
R/E, Follow-up, Period 2 Day 27, n=10.003 ± NA
R/E, Follow-up, n=150.010 ± 0.00270
SecondaryAssessment of Hematology Parameter: Hemoglobin

Blood samples for hematology assessment was collected for Hemoglobin. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Grams per Liter
Assessment of Hematology Parameter: Hemoglobin
Grams per LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Day -1, n=15144.7 ± 7.25
Period 1 Day 13, n=14143.5 ± 7.51
Period 2 Day 21, n=13146.4 ± 8.13
Period 2 Day 27, n=12144.2 ± 9.93
Follow-up, Period 1 Day 13, n=1137.0 ± NA
Follow-up, Period 2 Day 21, n=1147.0 ± NA
Follow-up, Period 2 Day 27, n=1146.0 ± NA
Follow-up, n=15140.1 ± 6.04
SecondaryAssessment of Hematology Parameter: Eryrocyte Mean Corpuscular Hemoglobin

Blood samples for hematology assessment was collected for Eryrocyte Mean Corpuscular Hemoglobin. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Picograms
Assessment of Hematology Parameter: Eryrocyte Mean Corpuscular Hemoglobin
PicogramsCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Day -1, n=1529.77 ± 1.457
On-treatment, Period 1 Day 13, n=1429.54 ± 1.536
On-treatment, Period 2 Day 21, n=1330.13 ± 1.329
On-treatment, Period 2 Day 27, n=1229.74 ± 1.466
Follow-up, Period 1 Day 13, n=129.30 ± NA
Follow-up, Period 2 Day 21, n=127.80 ± NA
Follow-up, Period 2 Day 27, n=130.90 ± NA
Follow-up, n=1529.49 ± 1.451
SecondaryAssessment of Hematology Parameter: Erythrocye Mean Corpuscular Volume

Blood samples for hematology assessment was collected for Erythrocyte Mean Corpuscular Volume. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Femtoliters
Assessment of Hematology Parameter: Erythrocye Mean Corpuscular Volume
FemtolitersCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Day -1, n=1584.60 ± 3.522
On-treatment, Period 1 Day 13, n=1487.94 ± 2.829
On-treatment, Period 2 Day 21, n=1385.39 ± 3.367
On-treatment, Period 2 Day 27, n=1287.73 ± 3.997
Follow-up, Period 1 Day 13, n=188.20 ± NA
Follow-up, Period 2 Day 21, n=179.20 ± NA
Follow-up, Period 2 Day 27, n=187.10 ± NA
Follow-up, n=1586.59 ± 3.618
SecondaryAssessment of Hematology Parameters: Erythrocytes and Reticulocytes

Blood samples for hematology assessment were collected for Erythrocytes and reticulocytes. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · 10^12 cells/Liter
Assessment of Hematology Parameters: Erythrocytes and Reticulocytes
10^12 cells/LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Erythrocytes, Day -1, n=154.870 ± 0.3068
Erythrocytes, On-treatment, Period 1 Day 13, n=144.869 ± 0.3400
Erythrocytes, On-treatment, Period 2 Day 21, n=134.868 ± 0.3173
Erythrocytes, On-treatment, Period 2 Day 27, n=124.855 ± 0.3605
Erythrocytes, Follow-up, Period 1 Day 13, n=14.680 ± NA
Erythrocytes, Follow-up, Period 2 Day 21, n=15.290 ± NA
Erythrocytes, Follow-up, Period 2 Day 27, n=14.730 ± NA
Erythrocytes, Follow-up, n=154.761 ± 0.3372
Reticulocytes, Day -1, n=150.043 ± 0.01246
Reticulocytes, On-treatment, Period 1 Day 13, n=140.040 ± 0.01350
Reticulocytes, On-treatment, Period 2 Day 21, n=130.040 ± 0.01097
Reticulocytes, On-treatment, Period 2 Day 27, n=120.028 ± 0.00997
Reticulocytes, Follow-up, Period 1 Day 13, n=10.064 ± NA
Reticulocytes, Follow-up, Period 2 Day 21, n=10.051 ± NA
Reticulocytes, Follow-up, Period 2 Day 27, n=10.014 ± NA
Reticulocytes, Follow-up, n=150.049 ± 0.01415
SecondaryAssessment of Hematology Parameters: Erythrocytes Distribution Width (EDW)

Blood samples for hematology assessment was collected for EDW. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Percentage of EDW
Assessment of Hematology Parameters: Erythrocytes Distribution Width (EDW)
Percentage of EDWCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Day -1, n=1512.91 ± 0.513
On-treatment, Period 1 Day 13, n=1413.13 ± 0.595
On-treatment, Period 2 Day 21, n=1312.89 ± 0.641
On-treatment, Period 2 Day 27, n=1212.90 ± 0.624
Follow-up, Period 1 Day 13, n=113.40 ± NA
Follow-up, Period 2 Day 21, n=113.60 ± NA
Follow-up, Period 2 Day 27, n=112.40 ± NA
Follow-up, n=1512.90 ± 0.535
SecondaryAssessment of Clinical Chemistry Parameters: Albumin and Protein

Samples for clinical chemistry assessment were collected for Albumin and Protein. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Grams per Liter
Assessment of Clinical Chemistry Parameters: Albumin and Protein
Grams per LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Albumin, Day -1, n=1545.2 ± 1.90
Albumin, On-treatment, Period 1 Day 13, n=1444.2 ± 2.58
Albumin, On-treatment, Period 2 Day 21, n=1343.4 ± 2.06
Albumin, On-treatment, Period 2 Day 27, n=1243.7 ± 1.87
Albumin, Follow-up, Period 1 Day 13, n=138.0 ± NA
Albumin, Follow-up, Period 2 Day 21, n=144.0 ± NA
Albumin, Follow-up, Period 2 Day 27, n=142.0 ± NA
Albumin, Follow-up, n=1542.7 ± 1.59
Protein, Day -1, n=1567.9 ± 3.98
Protein, On-treatment, Period 1 Day 13, n=1467.3 ± 3.22
Protein, On-treatment, Period 2 Day 21, n=1365.1 ± 3.82
Protein, On-treatment, Period 2 Day 27, n=1265.8 ± 4.00
Protein, Follow-up, Period 1 Day 13, n=160.0 ± NA
Protein, Follow-up, Period 2 Day 21, n=163.0 ± NA
Protein, Follow-up, Period 2 Day 27, n=170.0 ± NA
Protein, Follow-up, n=1563.7 ± 2.55
SecondaryAssessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT)

Samples for clinical chemistry assessment were collected for ALP, AST, ALT, CK and GGT. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · International units per Liter
Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT)
International units per LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
ALP, Day -1, n=1562.7 ± 14.52
ALP, On-treatment, Period 1 Day 13, n=1460.1 ± 14.34
ALP, On-treatment, Period 2 Day 21, n=1360.7 ± 13.94
ALP, On-treatment, Period 2 Day 27, n=1259.9 ± 17.83
ALP, Follow-up, Period 1 Day 13, n=151.0 ± NA
ALP, Follow-up, Period 2 Day 21, n=161.0 ± NA
ALP, Follow-up, Period 2 Day 27, n=156.0 ± NA
ALP, Follow-up, n=1560.7 ± 13.35
ALT, Day -1, n=1523.5 ± 7.07
ALT, On-treatment, Period 1 Day 13, n=1425.5 ± 8.83
ALT, On-treatment, Period 2 Day 21, n=1330.2 ± 20.12
ALT, On-treatment, Period 2 Day 27, n=1230.8 ± 29.65
ALT, Follow-up, Period 1 Day 13, n=1155.0 ± NA
ALT, Follow-up, Period 2 Day 21, n=139.0 ± NA
ALT, Follow-up, Period 2 Day 27, n=134.0 ± NA
ALT, Follow-up, n=1537.3 ± 23.40
AST, Day -1, n=1518.5 ± 3.62
AST, On-treatment, Period 1 Day 13, n=1420.7 ± 6.85
AST, On-treatment, Period 2 Day 21, n=1320.9 ± 5.87
AST, On-treatment, Period 2 Day 27, n=1223.3 ± 11.48
AST, Follow-up, Period 1 Day 13, n=183.0 ± NA
AST, Follow-up, Period 2 Day 21, n=126.0 ± NA
AST, Follow-up, Period 2 Day 27, n=137.0 ± NA
AST, Follow-up, n=1524.9 ± 9.44
CK, Day -1, n=15133.6 ± 40.31
CK, On-treatment, Period 1 Day 13, n=14227.1 ± 303.97
CK, On-treatment, Period 2 Day 21, n=13104.2 ± 43.44
CK, On-treatment, Period 2 Day 27, n=1288.7 ± 42.09
CK, Follow-up, Period 1 Day 13, n=11278.0 ± NA
CK, Follow-up, Period 2 Day 21, n=1177.0 ± NA
CK, Follow-up, Period 2 Day 27, n=1164.0 ± NA
CK, Follow-up, n=15144.3 ± 80.81
GGT, Day -1, n=1525.5 ± 14.97
GGT, On-treatment, Period 1 Day 13, n=1422.6 ± 13.20
GGT, On-treatment, Period 2 Day 21, n=1326.8 ± 23.95
GGT, On-treatment, Period 2 Day 27, n=1228.1 ± 28.25
GGT, Follow-up, Period 1 Day 13, n=117.0 ± NA
GGT, Follow-up, Period 2 Day 21, n=136.0 ± NA
GGT, Follow-up, Period 2 Day 27, n=182.0 ± NA
GGT, Follow-up, n=1536.1 ± 33.77
SecondaryAssessment of Clinical Chemistry Parameters: Direct Bilirubin (DB), Bilirubin and Creatinine

Samples for clinical chemistry assessment were collected for DB, bilirubin and creatinine. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Micromoles per Liter
Assessment of Clinical Chemistry Parameters: Direct Bilirubin (DB), Bilirubin and Creatinine
Micromoles per LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
DB, Day -1, n=153.5 ± 2.00
DB, On-treatment, Period 1 Day 13, n=143.5 ± 1.83
DB, On-treatment, Period 2 Day 21, n=132.4 ± 1.45
DB, On-treatment, Period 2 Day 27, n=122.2 ± 1.19
DB, Follow-up, Period 1 Day 13, n=14.0 ± NA
DB, Follow-up, Period 2 Day 21, n=11.0 ± NA
DB, Follow-up, Period 2 Day 27, n=12.0 ± NA
DB, Follow-up, n=152.9 ± 1.39
Bilirubin, Day -1, n=159.8 ± 6.72
Bilirubin, On-treatment, Period 1 Day 13, n=1410.1 ± 5.83
Bilirubin, On-treatment, Period 2 Day 21, n=136.6 ± 4.74
Bilirubin, On-treatment, Period 2 Day 27, n=125.3 ± 2.99
Bilirubin, Follow-up, Period 1 Day 13, n=110.0 ± NA
Bilirubin, Follow-up, Period 2 Day 21, n=13.0 ± NA
Bilirubin, Follow-up, Period 2 Day 27, n=15.0 ± NA
Bilirubin, Follow-up, n=157.9 ± 3.83
Creatinine, Day -1, n=1583.1 ± 7.71
Creatinine, On-treatment, Period 1 Day 13, n=1485.9 ± 11.02
Creatinine, On-treatment, Period 2 Day 21, n=1388.4 ± 9.43
Creatinine, On-treatment, Period 2 Day 27, n=1283.8 ± 10.69
Creatinine, Follow-up, Period 1 Day 13, n=164.0 ± NA
Creatinine, Follow-up, Period 2 Day 21, n=171.0 ± NA
Creatinine, Follow-up, Period 2 Day 27, n=191.0 ± NA
Creatinine, Follow-up, n=1580.7 ± 9.65
SecondaryAssessment of Clinical Chemistry Parameters: Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea

Samples for clinical chemistry assessment were collected for Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Mean · Millimoles per Liter
Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea
Millimoles per LiterCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Calcium, Day -1, n=152.31 ± 0.0539
Calcium, On-treatment, Period 1 Day 13, n=142.34 ± 0.0770
Calcium, On-treatment, Period 2 Day 21, n=132.29 ± 0.0720
Calcium, On-treatment, Period 2 Day 27, n=122.28 ± 0.0844
Calcium, Follow-up, Period 1 Day 13, n=12.27 ± NA
Calcium, Follow-up, Period 2 Day 21, n=12.38 ± NA
Calcium, Follow-up, Period 2 Day 27, n=12.06 ± NA
Calcium, Follow-up, n=152.28 ± 0.0400
Chloride, Day -1, n=15101.0 ± 1.73
Chloride, On-treatment, Period 1 Day 13, n=14100.5 ± 1.45
Chloride, On-treatment, Period 2 Day 21, n=13101.1 ± 2.40
Chloride, On-treatment, Period 2 Day 27, n=12101.8 ± 2.14
Chloride, Follow-up, Period 1 Day 13, n=1101.0 ± NA
Chloride, Follow-up, Period 2 Day 21, n=1100.0 ± NA
Chloride, Follow-up, Period 2 Day 27, n=199.0 ± NA
Chloride, Follow-up, n=15102.5 ± 2.07
Carbon Dioxide, Day -1, n=1525.6 ± 1.12
Carbon Dioxide, On-treatment, Period 1 Day13, n=1425.3 ± 1.38
Carbon Dioxide, On-treatment, Period 2 Day21, n=1327.4 ± 2.10
Carbon Dioxide, On-treatment, Period 2 Day27, n=1224.7 ± 3.11
Carbon Dioxide, Follow-up, Period 1 Day 13, n=125.0 ± NA
Carbon Dioxide, Follow-up, Period 2 Day 21, n=127.0 ± NA
Carbon Dioxide, Follow-up, Period 2 Day 27, n=120.0 ± NA
Carbon Dioxide, Follow-up, n=1525.7 ± 1.76
Glucose, Day -1, n=155.27 ± 1.077
Glucose, On-treatment, Period 1 Day 13, n=145.51 ± 0.487
Glucose, On-treatment, Period 2 Day 21, n=135.45 ± 0.399
Glucose, On-treatment, Period 2 Day 27, n=125.95 ± 1.103
Glucose, Follow-up, Period 1 Day 13, n=15.00 ± NA
Glucose, Follow-up, Period 2 Day 21, n=15.40 ± NA
Glucose, Follow-up, Period 2 Day 27, n=16.00 ± NA
Glucose, Follow-up, n=155.35 ± 0.374
Potassium, Day -1, n=154.22 ± 0.166
Potassium, On-treatment, Period 1 Day 13, n=144.29 ± 0.250
Potassium, On-treatment, Period 2 Day 21, n=134.36 ± 0.386
Potassium, On-treatment, Period 2 Day 27, n=124.29 ± 0.247
Potassium, Follow-up, Period 1 Day 13, n=13.90 ± NA
Potassium, Follow-up, Period 2 Day 21, n=14.00 ± NA
Potassium, Follow-up, Period 2 Day 27, n=14.10 ± NA
Potassium, Follow-up, n=154.31 ± 0.183
Sodium, Day -1, n=15141.1 ± 1.28
Sodium, On-treatment, Period 1 Day 13, n=14139.6 ± 1.82
Sodium, On-treatment, Period 2 Day 21, n=13140.3 ± 2.36
Sodium, On-treatment, Period 2 Day 27, n=12139.8 ± 2.09
Sodium, Follow-up, Period 1 Day 13, n=1139.0 ± NA
Sodium, Follow-up, Period 2 Day 21, n=1140.0 ± NA
Sodium, Follow-up, Period 2 Day 27, n=1137.0 ± NA
Sodium, Follow-up, n=15141.1 ± 2.02
Urea, Day -1, n=155.73 ± 1.4048
Urea, On-treatment, Period 1 Day 13, n=145.19 ± 1.0830
Urea, On-treatment, Period 2 Day 21, n=135.69 ± 1.3678
Urea, On-treatment, Period 2 Day 27, n=125.18 ± 1.2104
Urea, Follow-up, Period 1 Day 13, n=14.69 ± NA
Urea, Follow-up, Period 2 Day 21, n=12.79 ± NA
Urea, Follow-up, Period 2 Day 27, n=14.09 ± NA
Urea, Follow-up, n=155.34 ± 1.2189
SecondaryNumber of Participants With Abnormal Urinalysis Result

Samples for urinalysis assessment was collected at Day -1, Day 13, Day 21, Day 27 and during follow-up period (10 to 14 daya after last dose). Data for participants with abnormal urinalysis results has been presented.

Time frame:
Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Result
ParticipantsCAB 30 mgRBT 300 mg + CAB 30 mg
Number of Participants With Abnormal Urinalysis Result00
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

ECG measurements was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Data has been presented for Period 1, Day 14 pre-dose which showed abnormal- not clinically significant ECG finding. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day 1, 14, 21, 28 and follow-up (10 to 14 days after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsCAB 30 mgRBT 300 mg + CAB 30 mg
Number of Participants With Abnormal Electrocardiogram (ECG) Findings10
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs measurement was done in semi-supine position after 10 minutes rest and included SBP and DBP. Two blood pressure measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single blood pressure was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline to follow-up (10 to 14 days after last dose)
Reported as:
Mean · Millimeters of Mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of MercuryCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
SBP, On-treatment, Period 1 Day 14, n=14-2.5 ± 9.17
SBP, On-treatment, Period 2 Day 21, n=131.5 ± 11.90
SBP, On-treatment, Period 2 Day 28, n=120.5 ± 8.74
SBP, Follow-up, Period 2 Day 21, n=117.0 ± NA
SBP, Follow-up, n=153.7 ± 12.85
DBP, On-treatment, Period 1 Day 14, n=140.8 ± 7.61
DBP, On-treatment, Period 2 Day 21, n=132.0 ± 9.10
DBP, On-treatment, Period 2 Day 28, n=12-1.6 ± 4.21
DBP, Follow-up, Period 2 Day 21, n=19.5 ± NA
DBP, Follow-up, n=153.3 ± 9.04
SecondaryChange From Baseline in Pulse Rate

Vital signs measurement was done in semi-supine position after 10 minutes rest and included pulse rate. Two pulse rate measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single pulse rate was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline to follow-up (10 to 14 days after last dose)
Reported as:
Mean · Beats/minute
Change From Baseline in Pulse Rate
Beats/minuteCAB 30 mg Followed by RBT 300 mg + CAB 30 mg
On-treatment, Period 1 Day 14, n=14-4.5 ± 8.31
On-treatment, Period 2 Day 21, n=13-6.2 ± 9.98
On-treatment, Period 2 Day 28, n=123.4 ± 9.52
Follow-up, Period 2 Day 21, n=139.0 ± NA
Follow-up, n=15-1.3 ± 10.58

Adverse events

Collected over AEs and SAEs were collected from start of the study up to follow-up (up to 10 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB 30 mg0/15 (0%)0/15 (0%)1/15 (6.7%)
RBT 300 mg + CAB 30 mg0/14 (0%)1/14 (7.1%)7/14 (50%)
Most frequent serious events
Most frequent serious events
EventCAB 30 mgRBT 300 mg + CAB 30 mg
Alanine aminotransferase increasedInvestigations0/151/14
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCAB 30 mgRBT 300 mg + CAB 30 mg
LeukopeniaBlood and lymphatic system disorders0/151/14
NeutropeniaBlood and lymphatic system disorders0/151/14
PyrexiaGeneral disorders0/151/14
Viral infectionInfections and infestations0/151/14
Skin abrasionInjury, poisoning and procedural complications0/151/14
Body temperature increasedInvestigations0/151/14
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/151/14
HeadacheNervous system disorders0/151/14
HyperkeratosisSkin and subcutaneous tissue disorders0/151/14
ContusionInjury, poisoning and procedural complications1/150/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Mean43.7 ± 10.51
Sex: Female, Male
Sex: Female, Male(Participants)CAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Female0
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CAB 30 mg Followed by RBT 300 mg + CAB 30 mg
Asian - Central/South Asian Heritage1
White - White/Caucasian/European14
09

Study locations

1 site
  • GSK Investigational Site
    Cambridge, United Kingdom
10

References and documents

Publications

  • Ford SL, Lou Y, Lewis N, Kostapanos M, D'Amico R, Spreen W, Patel P. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. Antivir Ther. 2019;24(4):301-308. doi: 10.3851/IMP3306. PubMed 30896438 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Sep 2017, 3 months.

Results were first posted in Feb 2019, 1 year 4 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2017
First posted
May 11, 2017
StartActual
Jun 6, 2017
Primary completionActual
Sep 6, 2017
CompletionActual
Sep 7, 2017
Results first posted
Feb 4, 2019
Last update
Sep 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03149848
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 11, 2017
Start date
Jun 6, 2017
Primary completion
Sep 6, 2017
Completion
Sep 7, 2017
Results posted
Feb 4, 2019
Last update
Sep 17, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabotegravir · Rifabutin

Start the discussion